Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors

Executive Summary

The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.

You may also be interested in...



EQRx Price Disruptor Business Model Faces The Costly Reality Of FDA Drug Development Standards

Start-up firm, with two Chinese-developed drugs for lung cancer in late-stage development, may be particularly vulnerable to the US Food and Drug Administration’s recently stated opposition to the Chinese-only research supporting Eli Lilly’s sintilimab.

April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs

Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.

Broader Horizons For Advanced Biotech In 2022: New Targets, Settings For IO, Cell And Gene Therapy

US FDA’s user fee goal calendar for 2022 already contains 45 applications for novel agents featuring a wide array of biologics, from cell therapy in cancer and hematology to bispecifics and new immuno-oncology targets that could move the field beyond PD-1/L1.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel